Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Greg Jung who wrote (80)	9/24/1999 6:22:00 PM
From: Steve Push	Read Replies (1) \| Respond to of 360

Greg, It depends on which chip you are talking about. We purchase the GeneChip(R) from AFFX and use it, along with our READS(TM) technology, to build gene expression databases. We have our own chip, called the Flow-thru Chip(TM), that is in development and has a somewhat different application than the GeneChip. Since we have chosen the AFFX chip platform, it will be good for us if AFFX prevails in its patent dispute with INCY. The PTO decision was good news for us, but the patent dispute is not yet over. Steve Push VP, Corporate Communications Gene Logic Inc. genelogic.com